Drug intelligence / Profile preview

MIV-828

Development stage: Discontinued
Lead developer: Medivir
Modality: Small Molecules
Administration: Intravenous

Overview

MIV-828 is a nucleotide prodrug optimized for the treatment of acute myeloid leukemia (AML) and other hematological malignancies such as myelodysplastic syndrome and T-cell lymphoma. It is designed to overcome resistance mechanisms that limit the effectiveness of other nucleoside analogues. MIV-828 acts as a DNA synthesis inhibitor.

Targets

DNA polymerase family

Beyond the preview

Go deeper on MIV-828.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIV-828.

Explore the full profile